S&P BSE 150 Midcap Index News and Updates

Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on S&P BSE 150 Midcap Index from all sources in a single place.

Load latest

IDFC First Bank Ltd.

11 Jul 2025

72.95

-1.78%

IDFC First Bank Shares In Focus After UBS Initiates Coverage With 'Neutral' Rating

NDTV Profit

IDFC First Bank shares will be under radar during today's session after UBS initiated coverage on the stock with a 'neutral' rating.

IDFC First Bank Ltd. has gained 21.75% in the last 3 Months

Indian Renewable Energy Development Agency Ltd.

11 Jul 2025

160.00

0.63%

Zee, IREDA, TataElxsi, LemonTree, AegisLogistics, Nibe lead 15-stock watchlist for today's trade

Business Line

Will poor numbers sink IREDA? Shareholders throw a spanner in Zee's plans

Indian Renewable Energy Development Agency Ltd. has lost -22.43% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2210.00

-0.41%

Innovation validated; blockbuster potential unfolds

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

AbbVie partnership signals a new era for Glenmark Pharma (GNP) GNP’s subsidiary, Ichnos Glenmark Innovation (IGI), has signed an exclusive licensing agreement with AbbVie for its lead investigational asset, ISB-2001.

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2210.00

-0.41%

Stock Flash

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of Glenmark
Pharmaceuticals, has entered into an exclusive global licensing agreement
with AbbVie for the development and commercialization of IGI’s lead
oncology asset, ISB 2001. This first-in-class CD38×BCMA×CD3 trispecific
antibody is currently in Phase 1 clinical trials for relapsed/refractory multiple
myeloma (R/R MM).

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Tata Elxsi Ltd.

11 Jul 2025

6408.00

3.71%

Weak print; deal ramp-ups from Q2FY26

Sell: Tata Elxsi Ltd.

Target

ICICI Securities Limited

TATA Elxsi (TELX) reported a disappointing print vs I-Sec’s already muted estimates. Q1FY26 marks the fourth straight quarter of muted revenue performance.

Tata Elxsi Ltd. has gained 34.85% in the last 3 Months

JSW Infrastructure Ltd.

10 Jul 2025

314.00

-0.88%

CoC approves JSW Infra's resolution plan for NCR Rail Infrastructure

Business Standard

The Committee of Creditors (CoC) has approved JSW Infra's resolution plan for NCR Rail Infrastructure. The plan, subject to necessary regulatory approvals, aims to expand JSW Infra's logistics

Number of FII/FPI investors increased from 182 to 199 in Mar 2025 qtr.

Tata Elxsi Ltd.

10 Jul 2025

6408.00

3.71%

Tata Elxsi Results Earnings Call for Q1FY26

Conference Call with Tata Elxsi Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Crisil Ltd.

10 Jul 2025

6026.50

0.56%

Private sector debt recast firms' AUM may further shrink, says CRISIL

Business Standard

CRISIL forecasts a 4-6% drop in AUM for private asset reconstruction companies (ARCs) in FY26 due to subdued acquisitions of stressed loans and potential disruptions from loan securitisation